Local consolidative therapy in oligometastatic non-small-cell lung cancer after effective systemic treatment:who will benefit?  

作　　者：Jiayi Deng Mingyi Yang Qing Zhou 

机构地区：[1]School of Medicine,South China University of Technology,Guangzhou 510006,China [2]Guangdong Lung Cancer Institute,Guangdong Provincial People’s Hospital(Guangdong Academy of Medical Sciences),Southern Medical University,Guangzhou 510080,China

出　　处：《Cancer Biology & Medicine》2025年第1期21-27,共7页癌症生物学与医学(英文版)

基　　金：supported by grants from the Noncommunicable Chronic Diseases-National Science and Technology Major Project (Grant No. 2023ZD0501700);the National Natural Science Foundation of China (Grant No. 82373349);the MOE Changjiang Distinguished Professor Supporting Project (Grant No. KY0120240205)。

摘　　要：Non-small cell lung cancer (NSCLC), as the leading cause of cancer-related deaths, poses a serious health issue worldwide1,according to the Global Cancer Statistics 2022. Approximately 30% of NSCLC patients are diagnosed at an advanced or metastatic stage with a 5-year overall survival (OS) rate ranging from 7%-18%^(2). Unlike localized NSCLC, which can be treated with curative intent, patients with metastatic NSCLC typically undergo systemic treatment to delay progression and prolong survival.

关 键 词：METASTATIC cancer LUNG 

分 类 号：R734.2[医药卫生—肿瘤]